Phase 1 Trials In a first-in-human, randomized, placebo-controlled, single ascending dose, phase 1 trial in healthy participants, retatrutide demonstrated a favourable safety profile (similar to other incretin-based therapies) and early signs of efficacy with dose-dependent WL [42]
How do I interpret the test results
I am really good at collaborating and talking about material and saying, what about this
The anterior insula and human awareness
These effects are attributable to redox regulation by SFN, since (i) SFN induced ROS and in parallel GSH depletion in primary human T-cells and (ii) thiol-containing antioxidants abolished the immunosuppressive effect of SFN
Before committing to either, knowing your baseline NAD+ level tells you whether NAD+ deficiency is part of what youre dealing with, which changes how any protocol should be sequenced